97 related articles for article (PubMed ID: 19824900)
1. Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation.
Swaminathan S; Madkaikar M; Ghosh K; Vundinti BR; Kerketta L; Gupta M
Eur J Haematol; 2010 Feb; 84(2):180-2. PubMed ID: 19824900
[No Abstract] [Full Text] [Related]
2. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
Li WY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
[TBL] [Abstract][Full Text] [Related]
4. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
Portell CA; Sekeres MA; Rogers HJ; Tiu RV
Br J Haematol; 2012 Apr; 157(2):266-7. PubMed ID: 22150289
[No Abstract] [Full Text] [Related]
5. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis.
Zhang SJ; Li JY; Zhang JF; Finn J; Lu H; Xu W; Qian SX; Wu HX
Leuk Res; 2009 Aug; 33(8):e116-8. PubMed ID: 19328546
[No Abstract] [Full Text] [Related]
6. Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7.
Pich A; Godio L
Leuk Res; 2010 Feb; 34(2):e69-70. PubMed ID: 19744708
[No Abstract] [Full Text] [Related]
7. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.
Vicente C; Vázquez I; Marcotegui N; Conchillo A; Carranza C; Rivell G; Bandrés E; Cristobal I; Lahortiga I; Calasanz MJ; Odero MD
Leukemia; 2007 Nov; 21(11):2386-90. PubMed ID: 17581610
[No Abstract] [Full Text] [Related]
8. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
9. Morphologic and Molecular Characteristics of De Novo AML With
Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
[No Abstract] [Full Text] [Related]
10. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia.
Döhner K; Du J; Corbacioglu A; Scholl C; Schlenk RF; Döhner H
Haematologica; 2006 Nov; 91(11):1569-70. PubMed ID: 17043013
[TBL] [Abstract][Full Text] [Related]
12. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.
Andrikovics H; Nahajevszky S; Koszarska M; Meggyesi N; Bors A; Halm G; Lueff S; Lovas N; Matrai Z; Csomor J; Rasonyi R; Egyed M; Varkonyi J; Mikala G; Sipos A; Kozma A; Adam E; Fekete S; Masszi T; Tordai A
Leukemia; 2010 Oct; 24(10):1809-13. PubMed ID: 20811399
[No Abstract] [Full Text] [Related]
13. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
14. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
15. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
16. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
17. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
[TBL] [Abstract][Full Text] [Related]
18. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient.
Hsiao HH; Yang WC; Liu YC; Lee CP; Lin SF
Leuk Res; 2008 Aug; 32(8):1323-4. PubMed ID: 18078991
[No Abstract] [Full Text] [Related]
19. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
20. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]